Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The patient (or their guardian) is able to agree to take part in the study
- The patient is under 19 years old
- The patient has been diagnosed with Inflammatory Bowel Disease (IBD), which is a condition causing long-term inflammation in the digestive system (such as Crohn's disease or ulcerative colitis)
- The patient has been treated with a type of medication called anti-TNFα for their IBD for at least 3 months
- The patient had to stop taking their anti-TNFα medication because they developed a serious skin condition called psoriasis as a side effect, which did not get better with standard skin treatments, and this was confirmed by a skin doctor (dermatologist)
- The patient has since been switched to a different medication called Ustekinumab to continue treating their IBD
Who may not be able to join:
- The patient is 19 years old or older
- The patient does not have a confirmed diagnosis of IBD
- The patient stopped taking their anti-TNFα medication for any reason other than developing psoriasis as a side effect
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christine CHIAVERINI, Centre Hospitalier Universitaire de Nice
Phone: 04 92 03 47 02
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinumab treatment (M3-M6); Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinumab treatment (M3-M6); Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinumab treatment (M3-M6); Proportion of patients maintaining UC or CD control between anti-TNF-α discontinuation (M0) and 3-6 months of ustekinumab treatment (M3-M6)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.